Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody.

Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK.

Nature. 2013 Oct 24;502(7472):575-579. doi: 10.1038/nature12572. Epub 2013 Sep 22.

2.

Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.

Staus DP, Strachan RT, Manglik A, Pani B, Kahsai AW, Kim TH, Wingler LM, Ahn S, Chatterjee A, Masoudi A, Kruse AC, Pardon E, Steyaert J, Weis WI, Prosser RS, Kobilka BK, Costa T, Lefkowitz RJ.

Nature. 2016 Jul 21;535(7612):448-52. Epub 2016 Jul 13.

3.

Structural features of β2 adrenergic receptor: crystal structures and beyond.

Bang I, Choi HJ.

Mol Cells. 2015;38(2):105-11. doi: 10.14348/molcells.2015.2301. Epub 2014 Dec 24. Review.

4.

Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.

Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK.

Nature. 2011 Jan 13;469(7329):175-80. doi: 10.1038/nature09648.

5.

Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor.

Goetz A, Lanig H, Gmeiner P, Clark T.

J Mol Biol. 2011 Dec 9;414(4):611-23. doi: 10.1016/j.jmb.2011.10.015. Epub 2011 Oct 20.

PMID:
22037586
6.

Dynamic behavior of fully solvated beta2-adrenergic receptor, embedded in the membrane with bound agonist or antagonist.

Spijker P, Vaidehi N, Freddolino PL, Hilbers PA, Goddard WA 3rd.

Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4882-7. Epub 2006 Mar 21.

7.

Allosteric coupling from G protein to the agonist-binding pocket in GPCRs.

DeVree BT, Mahoney JP, Vélez-Ruiz GA, Rasmussen SG, Kuszak AJ, Edwald E, Fung JJ, Manglik A, Masureel M, Du Y, Matt RA, Pardon E, Steyaert J, Kobilka BK, Sunahara RK.

Nature. 2016 Jul 7;535(7610):182-6. Epub 2016 Jun 29.

PMID:
27362234
8.

Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?

Tang H, Wang XS, Hsieh JH, Tropsha A.

Proteins. 2012 Jun;80(6):1503-21. doi: 10.1002/prot.24035. Epub 2012 Mar 13.

9.

Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor.

Weiss DR, Ahn S, Sassano MF, Kleist A, Zhu X, Strachan R, Roth BL, Lefkowitz RJ, Shoichet BK.

ACS Chem Biol. 2013 May 17;8(5):1018-26. doi: 10.1021/cb400103f. Epub 2013 Mar 21.

10.

Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.

Kooistra AJ, Leurs R, de Esch IJ, de Graaf C.

J Chem Inf Model. 2015 May 26;55(5):1045-61. doi: 10.1021/acs.jcim.5b00066. Epub 2015 May 1.

PMID:
25848966
11.

Structure and function of an irreversible agonist-β(2) adrenoceptor complex.

Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK.

Nature. 2011 Jan 13;469(7329):236-40. doi: 10.1038/nature09665.

12.

Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.

Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, Kobilka B.

Nat Chem Biol. 2006 Aug;2(8):417-22. Epub 2006 Jun 25.

PMID:
16799554
13.

The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.

Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, Tate CG.

Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746.

14.

Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.

Reynolds KA, Katritch V, Abagyan R.

J Comput Aided Mol Des. 2009 May;23(5):273-88. doi: 10.1007/s10822-008-9257-9. Epub 2009 Jan 16.

15.

Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.

Huber T, Menon S, Sakmar TP.

Biochemistry. 2008 Oct 21;47(42):11013-23. doi: 10.1021/bi800891r. Epub 2008 Sep 27.

PMID:
18821775
16.

Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography.

Wacker D, Fenalti G, Brown MA, Katritch V, Abagyan R, Cherezov V, Stevens RC.

J Am Chem Soc. 2010 Aug 25;132(33):11443-5. doi: 10.1021/ja105108q.

17.

Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations.

Feng Z, Hou T, Li Y.

J Chem Inf Model. 2012 Apr 23;52(4):1005-14. doi: 10.1021/ci200594d. Epub 2012 Mar 29.

PMID:
22404225
18.

Covalent agonists for studying G protein-coupled receptor activation.

Weichert D, Kruse AC, Manglik A, Hiller C, Zhang C, Hübner H, Kobilka BK, Gmeiner P.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10744-8. doi: 10.1073/pnas.1410415111. Epub 2014 Jul 8.

19.

Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.

Katritch V, Reynolds KA, Cherezov V, Hanson MA, Roth CB, Yeager M, Abagyan R.

J Mol Recognit. 2009 Jul-Aug;22(4):307-18. doi: 10.1002/jmr.949.

20.

Structural insights into µ-opioid receptor activation.

Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, Kato HE, Livingston KE, Thorsen TS, Kling RC, Granier S, Gmeiner P, Husbands SM, Traynor JR, Weis WI, Steyaert J, Dror RO, Kobilka BK.

Nature. 2015 Aug 20;524(7565):315-21. doi: 10.1038/nature14886. Epub 2015 Aug 5.

Supplemental Content

Support Center